Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA sequencing of human gastric cancer drug treatment organoids

ABSTRACT: RNA sequencing of human gastric cancer drug treatment organoids

PROVIDER: PRJNA908849 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNA sequencing of human gastric cancer drug treatment organoids

Project description:Using RNA sequencing, we profile transcriptome dervied from human gastric cancer organoids after drug treatment.

2023-03-02 | GSE220137 | GEO

Patient-derived organoids for precise medicine in gastric cancer

Project description:Gastric cancer (GC) is a challenging malignant disease among gastrointestinal tumors. The clinical treatments for GC include surgery, neoadjuvant therapy and adjuvant chemotherapy. As patients’ response to chemotherapeutic drugs varies, an approach to predict the efficacy of chemotherapeutic treatment is urgently needed. Here, a biorepository of 17 human gastric tumor organoids (GTOs) and 9 normal organoids (GNOs) derived from GC patients was established, which contains the intestinal, diffuse and mixed-type of GC. GTOs retained morphologic, histopathological and genetic features of the tumors from which they were derived, and patient-derived organoid xenograft model indicated tumorigenicity of organoids. GTOs responses to clinically respective chemotherapy treatment positively correlated with the individual patient’s clinical response. Meanwhile, GNOs, which maintained original characteristics of corresponding tissues, could be separated from GTOs. The use of GNOs predicted the cytotoxic effect of chemotherapy on the organism. Our study implies that patient-derived organoids predict GC patient responses to chemotherapy and provide a solution for personalized treatment.

2024-03-10 | GSE235912 | GEO

Expression data from gastric cancer organoids

Project description:To understand the molecular basis of the acquisition of 5-FU resistance in gastric cancer stem cells, we established 5-FU-resistant gastric cancer organoids. We used microarrays to detail the global program of gene expression underlying 5-FU resistance and maintenance of stem cell properties in gastric cancer.

2020-07-10 | GSE154127 | GEO

RNA sequencing of gastric organoids treated with bacteria

Project description:We treated mouse gastric organoids with Helicobacter pylori, Fusobacterium nucleatum, and Neisseria subflava, and extracted RNA after 4 hours. RNAs were applied to RNA sequencing analysis to investigate bacteria-specific effects on gastric epithelial cells.

2024-04-29 | GSE202509 | GEO

Expression data from gastric cancer organoids

Project description:Expression data from gastric cancer organoids

| PRJNA645258 | ENA

Drug treatment

Project description:Drug treatment

| PRJNA1056274 | ENA

Human gastric organoids (34 days)

Project description:Human embryonic stem cells (WA01) were differentiated in a step-wise manner into three-dimensional human gastric organoids (hGOs). At day 34 of differentiation, the hGOs were collected and analyzed by RNA-sequencing.

2014-09-09 | E-MTAB-2885 | biostudies-arrayexpress

Metabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS

Project description:As metabolic rewiring is crucial for cancer cell proliferation, metabolic phenotyping of patient-derived organoids is desirable to identify drug-induced changes and trace metabolic vulnerabilities of tumor subtypes. We established a novel protocol for metabolomic and lipidomic profiling of colorectal cancer organoids by LC-QTOF-MS facing the challenge of capturing metabolic information from minimal sample amount (< 500 cells/injection) in the presence of extracellular matrix (ECM). The best procedure of the tested protocols included ultrasonic metabolite extraction with acetonitrile/methanol/water (2:2:1, v/v/v) without ECM removal. To eliminate ECM-derived background signals, we implemented a data filtering procedure based on p-value and fold change cut-offs which retained features with signal intensities >120% compared to matrix-derived signals present in blank samples. As a proof-of-concept, the method was applied to examine the early metabolic response of colorectal cancer organoids to 5-fluorouracil treatment. Statistical analysis revealed dose-dependent changes in the metabolic profiles of treated organoids including elevated levels of 2'-deoxyuridine, 2'-O-methylcytidin, inosine and 1-methyladenosine and depletion of 2'-deoxyadenosine and specific phospholipids. In accordance with the mechanism of action of 5-fluorouracil, changed metabolites are mainly involved in purine and pyrimidine metabolism. The novel protocol provides a first basis for the assessment of metabolic drug response phenotypes in 3D organoid models.

2021-10-12 | MTBLS2130 | MetaboLights

Human gastric organoids (34 days)

Project description:Human gastric organoids (34 days)

| PRJEB7176 | ENA

The transcriptomic changes of patient's derived colorectal cancer organoids induced by drug treatment.

Project description:The transcriptomic changes of patient's derived colorectal cancer organoids induced by drug treatment.

| PRJNA1213056 | ENA